新型降糖药物的降压作用

Antihypertensive effect of new hypoglycemic drugs

高血压和糖尿病是引起心脑血管事件的主要危险因素,对于血压处于130~139/80~89 mmHg(1 mmHg=0.133 kPa)的糖尿病患者,根据指南血压应控制在130/80 mmHg以下,但直接处方降压药物尚缺乏指南支持。三类新型降糖药中,SGLT-2抑制剂降压作用较明显,平均24 h动态收缩压/舒张压降低为3.8/1.8 mmHg;GLP-1受体激动剂仅降低收缩压,24 h动态收缩压下降范围在1.1~2.8 mmHg;DPP-4抑制剂降压作用研究结果不一致。三类新型降糖药对血压的影响,临床医生在治疗糖尿病患者时应酌情考虑。

Hypertension and diabetes are the major risk factors for cardiovascular and cerebrovascular events.For diabetes patients with blood pressure level 130-139/80-89 mmHg(1 mmHg=0.133 kPa),the target blood pressure should be controlled below 130/80 mmHg,but direct prescribing antihypertensive drugs is still lack of guidance.Among the three new hypoglycemic drugs,SGLT-2 inhibitor has obvious antihypertensive effect,and the average 24-hour dynamic SBP/DBP decrease to 3.8/1.8 mmHg;GLP-1 receptor agonist only decrease SBP,and the decrease range of 24-hour dynamic SBP is 1.1-2.8 mmHg;The results of studies on the antihypertensive effect of DPP-4 inhibitors are inconsistent.Three new types of hypoglycemic agents affect blood pressure.Clinicians should take into consideration for the treatment of diabetic patients.